Conference Coverage

Some with mild Crohn’s disease need no treatment


 

REPORTING FROM ACG 2019

Smoking cessation should be a top priority

“I spend a good portion of my time in clinic telling patients, ‘You can do more with stopping smoking than I can do with any of my medications,’ ” Dr. Isaacs said.

Another worthwhile intervention is to check for and correct low serum vitamin D levels. Vitamin D is a potent immunomodulator, and severely low levels below 15 ng/mL are associated with increased risk of Crohn’s disease relapse, more hospitalizations, more active disease activity, and heavier use of corticosteroids than in patients with moderate deficiency in the 15- to 30-ng/mL range (Nutrients. 2019 May 11;11[5]. doi: 10.3390/nu11051059).

Monitoring patients with mild Crohn’s disease

“Monitor closely for mucosal inflammation because if they start to progress, we want to get to them early so they get a good response to their first therapies. If the CRP starts moving up, consider doing something,” she advised.

A CRP above 5 mg/L is associated with a markedly increased risk of relapse. And Spanish investigators have shown in a prospective study of 95 patients in clinical remission for at least 6 months while on a tumor necrosis factor inhibitor that thereafter a fecal calprotein level greater than 300 mcg/g at any point was strongly predictive of relapse within the next 4 months (J Clin Gastroenterol. 2018 Mar;52[3]:229-34). Following a patient with mild Crohn’s disease over time endoscopically, it’s of value to utilize the Simple Endoscopic Score for Crohn’s Disease (SES-CD) to document that in fact the disease is mild. Dr. Isaacs recommended IG-IBD Scores – Calculators in Gastroenterology as “a great site” for assistance in calculating the SES-CD, the Harvey-Bradshaw Index, and a plethora of other inflammatory bowel disease scores.

She reported having no financial conflicts of interest.

Pages

Recommended Reading

Direct-acting antiviral treatment linked to lower mortality in patients with HCC history
Federal Practitioner
Machine-learning model predicts NASH based on common clinical and lab values
Federal Practitioner
Cilofexor passes phase 2 for primary biliary cholangitis
Federal Practitioner
Combo produces disappointing PFS, promising OS in metastatic colorectal cancer
Federal Practitioner
Rifabutin-based triple therapy for H. pylori gets high marks
Federal Practitioner
Nivolumab-ipilimumab combo has ‘robust’ clinical benefit in sorafenib-treated HCC patients
Federal Practitioner
Heavy metals linked with autoimmune liver disease
Federal Practitioner
TARGET-NASH: One-third of NAFLD, NASH patients lost weight, but not all kept it off
Federal Practitioner
Women experience more chemoradiotherapy toxicity in rectal cancer
Federal Practitioner
A triple-antibiotic cure for Crohn’s disease?
Federal Practitioner